Metformin and SGLT2 Inhibitor combo helps attain HbA1c of <8% in most Diabetics

Complex pathophysiology and multiple physiological factors play a key role in the onset and the progression of Diabetes Mellitus. Combination therapy rather than monotherapy plays a major role in the management of the disease (1). Out of these Metformin, a biguanide is the first line of treatment for type 2 diabetes mellitus. Another novel class of oral anti diabetic agents are Sodium glucose cotransporter 2 inhibitors (SGLT2i). Metformin and SGLT2 Inhibitor Dual Therapy in attaining the HbA1c threshold of <8% was done in the United States, states a study.

Published in the journal of Diabetes in June 2020,by Dominik Lautsch et al, the study aimed to determine factors associated with attaining the HbA1c threshold of <8% in the United States. The study was Observational, retrospective cohort study in adult type 2 diabetes mellitus patients. Data was collected from IQVIA EMR database. Observation period was June 2015 to June 2018. For this Patients needed to initiate SGLT2i and metformin without other antihyperglycemic agents. The impact of sociodemographic factors on achievement of HbA1c <8% was tested using multivariable logistic regression with backward stepwise selection using SAS 9.4.